(Total Views: 539)
Posted On: 04/30/2021 10:34:35 AM
Post# of 154227
Mesoblast MSC results at 60 days in Covid:
https://finance.yahoo.com/news/remestemcel-l-...00681.html
There are many similarities to LL's results in moderate-severe Covid.
What's interesting is that under 65 do better (46% improvement in mortality at day 60 vs. none in over 65; as a whole the trial failed and was stopped early on 12/17/20 for futility by DSMB), and they do even better when they also received steroids (75% improvement in mortality, p=0.006, for a "failed" trial). They further said that maybe the sicker, older patients just need more doses. They noted differences in care (more steroids) and patient age (much older) as the trial evolved. Sound familiar?
So, we weren't the only company having difficulties with Covid trial, and our DSMB wasn't the only one that failed to see subpopulations with good success, or the potential need for different dosing.
https://finance.yahoo.com/news/remestemcel-l-...00681.html
There are many similarities to LL's results in moderate-severe Covid.
What's interesting is that under 65 do better (46% improvement in mortality at day 60 vs. none in over 65; as a whole the trial failed and was stopped early on 12/17/20 for futility by DSMB), and they do even better when they also received steroids (75% improvement in mortality, p=0.006, for a "failed" trial). They further said that maybe the sicker, older patients just need more doses. They noted differences in care (more steroids) and patient age (much older) as the trial evolved. Sound familiar?
So, we weren't the only company having difficulties with Covid trial, and our DSMB wasn't the only one that failed to see subpopulations with good success, or the potential need for different dosing.
(11)
(0)
